Citations 2
Evaluation of the CosmosID Bioinformatics Platform for Prosthetic Joint-Associated Sonicate Fluid Shotgun Metagenomic Data Analysis
Wi, Yu Mi , Thoendel, Matthew , Raval, Yash S. , Greenwood‐Quaintance, Kerryl E. , Jeraldo, Patricio , Patel, Robin , Yan, Qun , Thoendel, Matthew J, Jeraldo, Patricio R , Chia, Nicholas , Patel, Robin , Yan, Qun , Abdel, Matthew P. , Chia, Nicholas , Thoendel, Matthew J , Raval, Yash S.
Journal of Clinical Microbiology | November 9, 2018 | Volume: 57 | Issue: 2 | Pages: No page available
We previously demonstrated that shotgun metagenomic sequencing can detect bacteria in sonicate fluid, providing a diagnosis of prosthetic joint infection (PJI). A limitation of the approach that we used is that data analysis was time-consuming and specialized bioinformatics expertise was required, both of which are barriers to routine clinical use.
Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms
Wi, Yu Mi , Greenwood‐Quaintance, Kerryl E. , Peck, Kyong Ran , Song, Jae‐Hoon , Patel, Robin , Patel, Robin , Schuetz, Audrey N. , Ko, Kwan Soo
Antimicrobial Agents and Chemotherapy | November 13, 2017 | Volume: 62 | Issue: 1 | Pages: No page available
ABSTRACT Although carbapenems are effective for treating serious multidrug-resistant Pseudomonas aeruginosa infections, carbapenem-resistant P. aeruginosa (CRPA) is now being reported worldwide. Ceftolozane-tazobactam (C/T) demonstrates activity against many multidrug-resistant isolates. We evaluated the activity of C/T and compared its activity to that of ceftazidime-avibactam (C/A) using a well-characterized collection of non-carbapenemase-producing CRPA isolates. Forty-two non-carbapenemase-producing CRPA isolates from a previous study (J. Y. Lee and K. S. Ko, Int J Antimicrob Agents 40:168–172, 2012, https://doi.org/10.1016/j.ijantimicag.2012.04.004 ) were included. All had been previously shown to be negative for bla IMP , bla VIM , bla SPM , bla GIM , bla SIM , and bla KPC by PCR. In the prior study, expression of oprD , ampC , and several efflux pump genes had been defined by quantitative reverse transcription-PCR. Here, antimicrobial susceptibility was determined by broth microdilution according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Time-kill curve assays were performed using three C/T- and C/A-susceptible CRPA isolates. Among 42 non-carbapenemase-producing CRPA isolates, overall susceptibility to C/T was 95.2%, compared to 71.4%, 42.9%, 23.8%, 21.4%, and 2.4% for C/A, ceftazidime, piperacillin-tazobactam, cefepime, and meropenem, respectively. The C/T resistance rate was significantly lower than that of C/A among isolates showing decreased oprD and increased mexB expression (5.1% versus 25.6%, P = 0.025, and 4.3% versus 34.8%, P = 0.022, respectively). In time-kill curve studies, C/T was less bactericidal than C/A against an isolate with decreased oprD and increased ampC expression. C/T was active against 95.2% of non-carbapenemase-producing CRPA clinical isolates. No apparent correlation of C/T MIC values with specific mutation-driven resistance mechanisms was noted.